Release Date: 31/10/12 14:20 Summary: Quarterly Activities Report and Cash Flow Price Sensitive: Yes Download Document 3.56MB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%